MARKET

RHHVF

RHHVF

Roche Hldg
OTCQX
244.37
NaN%
Closed 09:30 04/25 EDT
OPEN
--
PREV CLOSE
251.60
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
430.00
52 WEEK LOW
240.94
MARKET CAP
209.12B
P/E (TTM)
14.38
1D
5D
1M
3M
1Y
5Y
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Annual Meeting of the American Society of Clinical Oncology will be held in Chicago. The oral presentations will cover a range of topics including targeted therapies and immunologic therapies for various types of cancer. The plenary session will feature presentations on esophageal cancer, melanoma and lung cancer.
Seeking Alpha · 20h ago
Scholz promises support for pharma sector in Germany as Merck invests
German Chancellor Olaf Scholz promises support for pharma sector in Germany as Merck invests. Merck is investing 1.5 billion euros in Germany. The drugmaker plans to use its life sciences Advanced Research Centre in Darmstadt. Germany has sought to improve conditions for the pharma and biotech sector.
Reuters · 1d ago
DZ BANK AG Sticks to Its Buy Rating for Roche Holding AG (RHHVF)
TipRanks · 2d ago
GLOBAL MARKETS-Shares jump on tech boost; fragile yen on intervention watch
World stocks rise on Wednesday led by gains in the tech sector. Japan's yen touches 34-year low against the dollar and is on intervention watch. After-hours surge in shares of Tesla lifts sentiment in Asia and Europe. The euro rises to its highest in more than a week after strong euro zone PMIs.
Reuters · 2d ago
Artisan International Fund Q1 2024 Commentary
Seeking Alpha · 2d ago
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF)
TipRanks · 2d ago
UPDATE 1-Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump. The company's shares up 4% before the bell. Biogen has cut jobs and abandoned controversial drug Aduhelm to boost growth. Company says its new drug Leqembi recorded global sales of about $19 million.
Reuters · 2d ago
UBS Remains a Hold on Roche Holding AG (RHHVF)
TipRanks · 2d ago
More
About RHHVF
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Webull offers Roche Holding AG stock information, including OTCQX: RHHVF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RHHVF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RHHVF stock methods without spending real money on the virtual paper trading platform.